Dexcom exec: CGM is ‘undisputed standard of care’

SAN DIEGO – Dexcom’s next-generation G7 continuous glucose monitoring (CGM) system will empower users to take control of their health, says top company exec Kevin Sayer. 

Dexcom in December received clearance from the U.S. Food and Drug Administration for the device, which can be used for people with all types of diabetes ages two years and older. 

“The FDA approval of Dexcom G7 is a huge milestone for the diabetes community and underscores continued momentum in establishing continuous glucose monitoring as the undisputed standard of care for people with all types of diabetes,” said Kevin Sayer, chairman, president and CEO. “With an all-in-one wearable and completely redesigned mobile app, we’re confident G7 will improve and simplify diabetes management.” 

The G7 features a simplified, redesigned app experience; 30-minute sensor warm up; 12-hour grace period to replace finished sensors; and enhanced alerts—all packed into a 60% smaller wearable. 

Like its predecessor the G6, it also integrates with a wide range of lifestyle devices, including Apple Watch and Garmin, health and fitness apps, and insulin delivery systems. 

“By connecting to various mobile apps and devices, pumps and pens, we are able to give our users choice in how they manage diabetes and administer insulin,” said Sayer. 

Dexcom is working to ensure users will have equal access to the G7 through their insurance plans – Dexcom devices are currently reimbursed by more than 97% of private insurers. The company will also have a quick start program to allow commercially insured patients to receive special pricing until their health plan covers it. 

“Our mission is to empower people to take control of their health,” said Sayer. “With new devices like G7 hitting the market, we’re more determined than ever to expand access to CGM to more and more people with diabetes and will continue to work with private insurers, governments and nonprofit partners to help improve access to this life-changing technology.” 

• Read about the new AAHomecare diabetes council.